This Plain Language Summary of Publication article (PLSP) from Future Oncology describes a real-world study that examined treatment effectiveness in everyday settings for diffuse large B-cell lymphoma (DLBCL) patients. Using the CIBMTR® Database, researchers analyzed outcomes in 16 U.S. adults who received two sequential CD19-targeting therapies: loncastuximab tesirine (Lonca) followed by CAR-T therapy. The study evaluated treatment efficacy across the entire cohort and in two specific subgroups: patients who received Lonca as bridging therapy and those who received it as their final treatment before CAR-T therapy.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine’ and was published in the eJHaem.

Visit Wiley using the link to read the original article.